We describe total management results in a prospective series of 264 patients with aneurysmal subarachnoid hemorrhage (SAH) admitted to a neurologic unit. Referrals were actively solicited from general physicians as well as neurologists in the area. The diagnosis was based on computed tomography (CT). Secondary deteriorations were analyzed clinically and with serial CT scanning. Outcome was assessed 3 months after SAH. There were no relevant differences between the analyses of patients with and without an aneurysm confirmed by angiography or autopsy. One third of the patients either died within 1 day (12%) or remained in a poor clinical condition that precluded surgery (22%). One third were in good clinical condition, but contraindications to surgery were judged present or serious complications occurred before surgery could be performed. One third of all patients underwent surgery. Overall mortality in our series was 52%; only 26% made a good recovery. The risk of rebleeding was not related to the patients' initial clinical condition, but all other intracranial complications occurred significantly more often in patients graded poor compared with patients in good clinical condition. The most important causes of death and severe disability were hemorrhage (16%), recurrent hemorrhage (18%), and delayed cerebral ischemia (15%). The most important surgical complication was delayed deterioration caused by ischemia (20% of operated patients). We estimated that recognition of 'warning leaks,' surgery in patients over 65, and improvement of our surgical technique could decrease mortality from 52% to approximately 41%. (Stroke 1987; 18:1061-1067)
A dvances in the treatment of patients with aneu-/ \ rysmal subarachnoid hemorrhage (SAH) A. X . have changed the outlook for individual patients who receive surgical treatment. Yet, substantial improvements in surgical mortality and morbidity do not seem to have had much impact on the clinical course of SAH when the total patient population is studied.
1 " 3 It has been estimated that one third either die or remain disabled with the first hemorrhage. One half of all patients deemed fit for surgery develop serious complications that prevent operation. 2 These figures are derived from population studies predominantly using mortality as a measure of outcome and lacking much clinical detail. Hospital-based studies give more information about the complications but are often from secondary referral centers receiving patients who have survived immediate death and early complications and may provide an optimistic view not characteristic of the total spectrum of patients.
We report our prospective experience with a hospital series of patients with SAH that contains almost the entire spectrum of the disease, with detailed documentation of clinical events and outcome.
Subjects and Methods
The University Hospital 'Dijkzigt' is the only hospital in Rotterdam where intracranial surgery is performed. It serves the city of Rotterdam and its surroundings, with a population of approximately 1.5 million. There are 15 hospitals in the city and region, of which 13 refer every patient with SAH, whether fit for surgery or not, immediately to our hospital.
The study period was from October 1977 to January 1983, when we conducted a clinical trial to test the effect of tranexamic acid on the incidence of rebleeding. 4 In every year of the study period, we sent a letter to all general practitioners in the area in which we emphasized the clinical symptoms and signs of SAH and asked them to refer all patients in whom SAH was suspected to our hospital as soon as possible, regardless of clinical condition.
Criteria for Diagnosis of Subarachnoid Hemorrhage
SAH was diagnosed if this diagnosis was suspected on clinical grounds and computed tomography (CT) showed subarachnoid blood compatible with aneurysmal hemorrhage. We relied especially on the presence of blood in the basal cisterns and fissures and on the absence of lesions other than aneurysms that could explain the subarachnoid hemorrhage. 5 In a few patients in whom CT showed no abnormality, demonstration of blood and blood pigments by lumbar puncture was considered diagnostic. We did not apply a time limit for the interval between SAH and admission, as long as the diagnosis could be ascertained by CT or lumbar puncture. Since angiography was per-formed only in patients who were suitable for surgery and since we did not want to restrict our study to this type of patient, angiographic demonstration of an aneurysm was not an inclusion criterion. On the other hand, patients who met the above-mentioned criteria for SAH but in whom angiography failed to show an aneurysm were excluded from the study.
Previous Episodes of Probable Subarachnoid Hemorrhage
Since probable SAH in the 4 weeks preceding the episode that led to admission was an exclusion criterion for the tranexamic acid study, patients and relatives were asked extensively about previous episodes of sudden severe headache.
Clinical Condition on Admission
The clinical condition on admission of each patient was categorized according to the original Hunt and Hess grading system (without modification by serious systemic disease or vasospasm 6 ) and also on the 14-point Glasgow Coma Scale. 7 
Treatment Protocol
All patients were under continuous observation in an intensive care unit until a few days after surgery or, in patients who did not undergo surgery, for 4 weeks. CT was performed on admission and was repeated weekly and after any clinical deterioration. All patients were treated with bed rest for 6 weeks if no surgery was performed. Meperidine was used as an analgesic, and hypertension (diastolic blood pressure > 110 mm Hg) was treated with clonidine unless adequate control could not be reached with these drugs. Patients who developed hyponatremia (serum sodium level < 135 mmol/1) were treated with fluid restriction until serum sodium became normal. The antifibrinolytic agent tranexamic acid was used (by random allocation) in 86 patients, 6 g/day in the first week and 4 g/day in the next 3 weeks, or until surgery if it was performed within 4 weeks. Eighty-nine patients received placebo treatment in a similar fashion. Eighty-nine patients were not included in the tranexamic acid study because of a delay of > 7 2 hours after the hemorrhage (54 patients), contraindications to the drug (3 patients) or apparent imminent death (32 patients).
Surgery, if feasible, was usually planned for the end of the second week. A patient was considered fit for surgery if he opened his eyes spontaneously, was oriented and rational, and had no severe extracranial complications (see below). These criteria conform to the Hunt and Hess Grades 1 and 2. The presence and severity of vasospasm on the angiogram was sometimes used in the decision to operate, but angiography was performed within a few days after admission and was rarely repeated preoperatively. A stable focal hemispheric deficit (from a hematoma or ischemia), neck stiffness, or headache were not contraindications. Patients > 6 5 years old were not operated on, even when in good clinical condition. Ventricular shunting for hydrocephalus was performed only in some symptomatic patients, but indications changed during the study period. 8 
Definitions of Clinical Events
Every clinical deterioration was analyzed.
Rebleeding. Rebleeding was diagnosed when an increase of subarachnoid, intracerebral, or intraventricular blood could be demonstrated by CT or autopsy compared with the previous CT scan.
Delayed cerebral ischemia. Delayed cerebral ischemia (DCI) was diagnosed when a patient developed a decrease in the level of consciousness, focal signs, or both, and when CT scanning showed radiolucent areas compatible with the clinical signs, or when no other changes could explain the deterioration.
Hydrocephalus. Hydrocephalus was diagnosed when a patient developed a decreased level of consciousness for which no explanation could be demonstrated other than enlargement of the ventricles, defined as a bicaudate index >95th percentile for age. 8 Other intracranial complications. Epilepsy or a progressive mass effect of an intracerebral, Sylvian, or subdural hematoma, accompanied by a decrease in the level of consciousness, and/or focal hemispheric signs were classified as other intracranial complications.
Extracranial complications. Pneumonia, sepsis, symptomatic cardiac arrhythmias, heart failure, myocardial infarction, gross gastrointestinal hemorrhage, and symptomatic hyponatremia were considered extracranial complications.
Outcome Assessment
Three months after the SAH, outcomes were classified according to the 5-point Glasgow Outcome Scale.
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Results
Two hundred seventy patients met the inclusion criteria. In 3 other patients SAH was very probable on clinical grounds, but they died within hours after admission before CT could be performed, and autopsy was not permitted. An additional 52 patients with clinical signs and CT evidence of SAH were excluded because angiography was negative (38 patients) or showed an arteriovenous malformation (14 patients). In 6 of the 270 patients documentation was lost (they were dead or moribund on admission); 264 patients were analyzed.
Admission rate increased during the years of the study: 2 patients in the last 2 months of 1977, 32 in 1978, 50 in 1979, 58 in 1980, 57 in 1981, and 65 in 1982. The aneurysmal origin of the SAH was proved with angiography or at autopsy in 176 patients (67%). In the remaining 88 patients, the diagnosis of SAH was based on CT evidence only. 5 These patients did not undergo angiography because of age or clinical condition and thus represent a negative selection. On the other hand, a few patients without an aneurysm (and consequently with a good prognosis) may inadvertently have been included. Therefore, all data have been analyzed separately for patients with and without a demonstrated aneurysm. The interval between SAH and admission, the age distribution, and the clinical condition on admission are presented in Tables 1-3 .
According to management, 5 classes could be distinguished ( Figure 1) :
Class A. Thirty-two patients died within 24 hours after the first clinical signs of SAH. Ten of these patients acutely deteriorated within hours of an initial episode of lesser severity but before investigation with CT.
Class B. Fifty-eight patients were never suitable for surgery in a period of 4 weeks after SAH because of poor clinical condition from the outset.
Class C. Forty-two patients in neurologically good clinical condition did not undergo surgery. In 31 patients, the reason for this was age > 65, and in the other patients the reason was unstable angina, psychosis, insufficient cerebral blood flow after trial ligation of the carotid artery in a patient in whom this treatment was judged the only suitable surgical therapy, terminal cancer, incomplete angiography because of complications during the procedure, and impaired pulmonary function (1 patient each). In 1 patient, an initial diagnosis of cerebral contusion was proved wrong by a fatal aneurysmal rebleed. In 2 patients the aneurysm was considered inoperable, and 2 patients refused surgery.
Class D. Thirty-nine patients were suitable for surgery but had serious complications in the preoperative period that precluded surgery.
Class E. Ninety-three patients underwent surgeryclipping of the aneurysm in 91, carotid ligation in 1, and proximal clipping of the anterior cerebral artery (Logue procedure) in 1.
In Table 4 , the nature and number of preoperative complications and mortality and morbidity after 3 months are presented for each management group. Because in previous studies the risks of rebleeding 10 " 12 and DCI' 2 were related to the initial clinical condition, the occurrence of each complication is presented separately for 3 categories of patients according to their Hunt and Hess grade on admission (Table 5 ). In all patients who survived > 2 4 hours (Classes B-E), rebleeding was not related to Hunt and Hess category, but the other complications occurred more often in patients with an initially poor clinical condition. This trend was significant (test for linear trend 13 ) for DCI (p = 0.0002), hydrocephalus (p<0.0001), and other intracranial complications (p = 0.0050); p value for extracranial complications was 0.0522.
Since management was not uniform with respect to antifibrinolytic treatment, complications and outcome are separately presented for 3 treatment groups of patients in Table 6 . Rebleeding occurred significantly more often in the placebo group compared with the antifibrinolytic group (x 2 = 8.02, p < 0 . 0 1 ) , whereas the reverse is true for DCI (x 2 = 4.38,p<0.05). These differences were also significant in all patients in the clinical trial of tranexamic acid, which included patients from other institutions. 4 Severe disability occurred more often in the nontrial group compared with the placebo group (x 2 = 5.34, p < 0 . 0 5 ) . No other differences were significant.
In Table 7 , the complications that caused death or severe disability are presented. In 38 patients (14%) who had 2 or more complications, the complication that contributed most to death or disability was counted.
Previous episodes of sudden severe headache for which no medical attention was sought or which had not been recognized as SAH by a physician had occurred in 48 patients (18%; 3 patients in Class A, 11 in B, 5 in C, 6 in D, and 23 in E).
Discussion
Our findings reemphasize the seriousness of SAH. The overall mortality in our series was 52%, and only 26% made a good recovery. One third of our patients In 33% of our patients the aneurysmal origin of the SAH was not proved. This has introduced a net bias toward poorer outcome since patients without a proved aneurysm were admitted earlier (Table 2 ) and in a worse clinical condition (Table 3 ). There were no important differences in the occurrence of specific complications between patients with a proved aneurysm and other patients (Table 4) . However, even after the 32 patients who died within 24 hours are excluded, 76% of the patients with an unproved aneurysm died or remained severely disabled, whereas this occurred in 53% of the other patients (x 2 = 10.79, /?<0.01). How well does our series represent the whole spec-
FIGURE 1. Classification of 264 patients with aneurysmal subarachnoid hemorrhage according to management (for detailed description of each class see "Results").
trum of patients with SAH? Our methods of case finding and of diagnosis by CT scanning cover the middle ground between true population studies (with maximal inclusiveness but uncertain accuracy of the diagnosis) and series from neurosurgical centers (unequivocal diagnosis but heavy selection bias). The simple fact that during the 5-year study period our admission rate doubled from 32 to 65 per 1.5 million inhabitants indicates that not all patients with SAH were admitted to our hospital, at least not in the early years. But even a yearly incidence of 4.3/100,000 is still less than the 8/100,000 in a Dutch population study 14 and considerably less than the rate of 11-19/100,000 from population studies in other countries.
l5~20 Though in a hospital study the early mortality figure must necessarily be lower than that in the general population, our incidence of 12% compares with the 10% of a Mayo Clinic population study. l6 An incidence of 30% has also been found. ' 5 Based on these considerations, we think that a large part of the clinical spectrum of SAH is included in our series, though it cannot be regarded as a population study.
It has been repeatedly argued that many patients could be saved if warning leaks were recognized and patients promptly operated upon.'- 21 At least 48 patients (18%) had such unrecognized episodes. Fourteen were in Classes A and B, and 10 of them died. They could have been in the "better" Classes C, D, and E had their earlier episode been identified as SAH. The incidence of warning leaks may have been underestimated in our series since not all patients were suitable for the tranexamic acid study and since patients who were excluded perhaps were not questioned as thoroughly in this respect.
One might argue that age > 65 should not be a contraindication for surgery -a reasonable proposition in the face of 58% mortality in these patients (18 of 31 patients over age 65 in Class C). The presumed high risk of extracranial complications in elderly patients has been used as an argument for conservative therapy, but in our series 15 of the 18 lethal complications in patients > 6 5 were rebleeding or DCI.
Surgical mortality in our series was 17%, which is high for surgery at the end of the second week compared with a number of series from single neurosurgical centers, 22 " 32 in which it varies from nil 24 to 9%, w with a mean of 5%. The combined results of 11 centers participating in the Cooperative Aneurysm Study, however, showed a mortality of 13%." The most important cause of surgical mortality in our patients was postoperative cerebral ischemia (13 of 93, 14%). An explanation for the high incidence and the severity of this complication may be our policy of fluid restriction in patients who developed hyponatremia. 34 Since we changed this regime (after 1983), surgical mortality declined to 5% (of 126 operations), but other measures, such as improvement of surgical skill, may also have contributed.
The question of whether the timing of surgery at the end of the second week is appropriate has not yet been settled. 35 In 39 (Class D) of the 132 (Classes D and E; 30%) patients who were initially operable, surgery could not be performed because serious complications occurred in the 10-14 days during which patients were awaiting surgery. Mortality caused by these complications was 27 of 132 (20%). This means that even with our high surgical mortality of 17%, the results of early surgery might be somewhat better than those of delayed surgery if one assumes that the surgical risk would be the same. An important advantage of early surgery might be that postoperative ischemia can be treated with induced hypertension and hypervolemia, 36 -37 which may still further reduce surgical mortality. Yet, too many assumptions would have to be made on the basis of our data to calculate the possible benefits of early surgery.
Ninety patients (Classes A and B, 34%) were not suitable for surgery within the 4 weeks after SAH, and many of them died within a short time. Remediable conditions that may lead to an initially poor clinical condition are intracerebral hematoma and acute hydrocephalus. In a previous study 38 we found that the site and extent of a hematoma cannot always explain a poor clinical condition, that a hematoma is often combined with extensive intraventricular hemorrhage, and that even a purely subarachnoid hemorrhage can lead to severe brain damage and early death. It is therefore unlikely that removal of hematomas would lead to substantial changes in total outcome. Ventricular shunting in patients with acute hydrocephalus may improve their clinical condition dramatically, but even then, patients with acute hydrocephalus have an increased risk of developing DCI and rebleeding, 8M which may negate the positive effect of shunting. Again, our data do not permit a quantitative analysis of the possible benefits of hematoma surgery and ventricular shunting.
In general, prevention of intracranial complications remains the most important strategy in trying to decrease mortality and morbidity from SAH. Rebleeding and DCI are the most important of these complications and occurred in 25 and 27%, respectively. These proportions may have been influenced by the fact that one third of our patients were treated with the antifibrinolytic drug tranexamic acid, which prevents most rebleeds but also provokes DCI to such an extent that outcome is not benefitted 40 (see also Table 6 ). The further improvement of prevention and treatment of DCI is therefore the most crucial problem in the management of patients with SAH.
